Free Newsletter
Merck expands Januvia label
In a sort of good news/bad news move, the FDA is allowing Merck to expand marketing of the diabetes drug Januvia--but it's also expanding the warnings on Januvia's label.
Now, Merck can sell the drug for use in combo with other diabetes meds, rather than as a supplement to diet and exercise alone. The new label will highlight warnings of hypersensitivity reactions, including the rare-but-deadly Stevens-Johnson syndrome.
- take a look at Merck's release
- read the report from the Houston Chronicle
Related Articles:
ADA meeting sees new data on diabetes drugs. Report
FDA expected to approve Januvia soon. Report
Comments
Post new comment
Paid Research Reports
- The Top 10 Biosimilar Players: Positioning, performance and SWOT analyses
- New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency
- Stakeholder Opinions: Vaccine antigen delivery technologies - Molecular systems to open new markets
- The Top 10 Contract Research Organizations
- Stakeholder Opinions: Vaccine administration technologies - Beyond needles
- Future Pharmaceutical Industry Trends: Long-term opportunities tempered by short-term challenges





Click here to get the FiercePharma email newsletter for FREE!
Be the first to comment